Results 301 to 310 of about 219,223 (326)

FAK inhibitor treatment systemically regulates the glioblastoma immune environment via blocking monocyte trafficking

Webb ER, Black A, Carrasco G, Furqan M, Hollis RL, Loftus AEP, Ochoa JC, Enjalbert R, Best T, Peng B, Muir M, Laing F, Lee M, Al Shboul S, Wang T, Smith C, Hupp TR, Rajan A, Alfaro JA, Brennan PM, Liu Z, Ginhoux F, Bernabeu MO, Serrels A, Gentek R, Frame MC, Brunton VG.   +26 more
europepmc   +1 more source

Fak and focal adhesions.

Japanese journal of cancer research : Gann, 1996
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

New Insights on Fak and Fak Inhibitors

Current Medicinal Chemistry, 2021
Background: Focal adhesion kinase (Fak) is a cytoplasmic protein tyrosine kinase overexpressed and activated in different solid cancers; it has shown an important role in metastasis formation, cell migration, invasion and angiogenesis and consequently it has been proposed as a potential target in cancer therapy, particularly in a metastatic phase. In
C. Brullo, B. Tasso
openaire   +3 more sources

Pyk 2 FAKs, any two FAKs

Cell Biology International, 2003
Recent data suggest a novel and significant role for the protein tyrosine kinase Pyk2/CAK /RAFTK in cytoskeletal remodeling, proliferation and motility of adherent cells, such as epithelial cells and fibroblasts, possibly putting this kinase in direct competition with its close cousin, the focal adhesion kinase, FAK. Within a three-month period in late
openaire   +2 more sources

Educational Issues In Fak Fak, West Papua Province

2018
Proceedings of the Education Research Colloquium between Faculty of Education, Universiti Teknologi Malaysia (UTM) & Universitas Negeri Makassar, Indonesia.
NikoToturup, Patak, Andi Anto
openaire   +1 more source

PYK2 and FAK in osteoclasts

Frontiers in Bioscience, 2003
Integrin alpha(v)beta3 plays a pivotal role in osteoclastic bone resoprtion by mediating both osteoclast attachments on bone matrix and cytoskeleton reorganization. The focal adhesion kinase (FAK) family kinases including FAK and proline-rich tyrosine kinase 2 (PYK2) are major tyrosine kinases activated by integrin engagement.
Wen-Cheng, Xiong, Xu, Feng
openaire   +2 more sources

FAK Goes Nuclear

Science Signaling, 2008
Under normal growth conditions, the tumor suppressor protein p53 is ubiquitinated and degraded, and cells proliferate. However, when cells are under stress, p53 accumulates and induces the expression of the gene encoding p21, which triggers cell cycle arrest.
openaire   +1 more source

Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency

Bioorganic & Medicinal Chemistry Letters, 2016
Herein, we describe the synthesis of Pyk2 inhibitors via macrocyclization of FAK and dual Pyk2-FAK inhibitors. We identified macrocycle 25a as a highly potent Pyk2 inhibitor (IC50=0.7nM), with ∼175-fold improvement in Pyk2 potency as compared to its acyclic counterpart.
Julie, Farand, Nicholas, Mai, Jayaraman, Chandrasekhar, Zachary E, Newby, Josh, Van Veldhuizen, Jennifer, Loyer-Drew, Chandrasekar, Venkataramani, Juan, Guerrero, Amy, Kwok, Ning, Li, Yelena, Zherebina, Sibylle, Wilbert, Jeff, Zablocki, Gary, Phillips, William J, Watkins, Robert, Mourey, Gregory T, Notte   +16 more
openaire   +2 more sources

Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders

Biochemical Pharmacology
Focal adhesion kinase (FAK), a non-receptor tyrosine kinase, plays an essential role in regulating cell proliferation, migration and invasion through both kinase-dependent enzymatic function and kinase-independent scaffolding function. The overexpression and activation of FAK is commonly observed in various cancers and some drug-resistant settings ...
Ming Yang, Hua Xiang, Guoshun Luo
openaire   +2 more sources